First Lady Marie Louise "Liza" Araneta-Marcos on Saturday graced the opening of the Bagong Bayani ng Mundo – OFW Serbisyo ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
Morning Overview on MSN
Why cancer returns years later, and how we can stop it
Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...
An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...
Patients recently diagnosed with cancer show an increased risk for major bleeding after myocardial infarction, with the risk ...
CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that utilizes artificial intelligence ...
Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...
For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback